



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

NOV 27 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. Thomas E. Finch, III
Vice President
Teftec Corporation
6929 Old Spring Branch Road
Spring Branch, Texas 78070

Re: K983066
Trade Name: FirstClass™ Powered Tilt Seat
System, Model S300
Regulatory Class: II
Product Code: ITI
Dated: August 19, 1998
Received: September 2, 1998

Dear Mr. Finch:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read 'C. Witten', is written over the typed name.

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Page 1 of 1

510 (k) NUMBER (IF KNOWN): K983066DEVICE NAME: FirstClass™ Power Tilt Seat System Model S300

INDICATIONS FOR USE:

The TEFTEC Corporation FirstClass™ Power Tilt Seating System has been designed for use by anyone needing pressure relief while in a seated position.

The FirstClass™ Power Tilt Seating System could provide pressure relief by postural change for persons having the following condition or injury:

Spinal Cord Injury (SCI)
Head Injury (CHI)
Muscular Dystrophy (MD)
Cerebral Palsy (CP)
Hyper Reflexia
Chronic Pain
Burn Trauma Patient
Severe Scar Tissue build up
Brown Sequard's Syndrome
Multiple Sclerosis
Heterotrophic Ossification
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Quadriplegia
Cerebral Palsy
Paraplegia
Proximal Extremity Weakness
Cerebral Vascular Accident (CVA or Stroke)

This is not meant to be an all-inclusive list. Anyone needing pressure relief or positional change that is unable to facilitate those movements independently, would be able to accomplish them with this unit. This would usually be decided by clinical evaluation of the client's strength, sensation level, upper extremity strength, mobility needs and seating needs.

(Please Do Not Write Below This Line-Continue On Another Page If Needed.)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use _____
(Per 21 CFR 801.109)

Revised 11/13/1998

OR
Over-The-Counter-Use X
(Optional Format 1 (2 - 96))
[Signature]
(Division Sign-Off)
Division of General Restorative Devices
510(k) Number K983066